PharmNovo signs agreement with Worldwide Clinical Trials for phase IIa study of PN6047 in neuropathic pain
PharmNovo, a Swedish pharmaceutical company developing neuropathic pain treatments, announces its collaboration with Worldwide Clinical Trials, a full-service contract research organisation (CRO), to conduct the phase IIa study of PN6047.The study is planned to start in 2024.
In the upcoming phase IIa study, PharmNovo will investigate the safety, tolerability, pharmacokinetics, and efficacy of their drug candidate PN6047 for individuals affected by neuropathic pain and experiencing Mechanical Allodynia. This distressing symptom, caused by nerve injury, often disrupts daily life and sleep. PN6047 offers a targeted approach to alleviate this condition, aiming to improve the overall pain experience. Insights on its efficacy will aid in designing subsequent phase IIb/III studies.
"Our collaboration with Worldwide Clinical Trials is a significant step in our dedication to addressing the complex challenges of neuropathic pain. Their expertise was instrumental in our decision to partner together. With early promising results from PN6047, we are optimistic about its potential to make a difference. As we prepare for the phase IIa study, scheduled to launch in 2024, our mission is clear: to deepen our understanding and move forward toward a solution that truly enhances the quality of life for those affected," says Per von Mentzer, CEO of PharmNovo.
"At Worldwide Clinical Trials, our focus is on partnering with companies like PharmNovo to create customised solutions that advance new medications. The phase IIa study of PN6047 is an exciting opportunity, and we're fully devoted to ensuring its success while furthering our collective understanding of neuropathic pain solutions," says Peter Benton, President and Co-CEO at Worldwide Clinical Trials.
For more information, please contact:
Per von Mentzer, CEO
Phone +46 705 44 32 50
Email: per.von.mentzer@pharmnovo.com
About PharmNovo
PharmNovo AB is a clinical-stage pharmaceutical company focused on developing safe and effective drugs for neuropathic pain. In this area, there is currently a lack of sufficient treatments. The company's drug candidate, PN6047, effectively reduces neuropathic pain in animal models. The company also sees clinical potential in other areas: chronic cough and opioid withdrawal syndrome (OWS). PharmNovo, headquartered in Medicon Village in Lund, Sweden, was founded in 2008 by Dr. Bengt von Mentzer, who has more than 30 years of experience in drug development and pain research at AstraZeneca. The team comprises prominent researchers in academia and industry, and the company has an extensive international network of leading expert advisors. To learn more, visit pharmnovo.com and follow PharmNovo at LinkedIn.
Tags:
